Pharma firm clears key hurdles in plan to launch imaging clinic chain
A Canadian pharmaceutical firm has cleared key hurdles in its plan to launch a chain of imaging clinics dedicated to Alzheimer’s disease.
Last year, Vancouver-based Algernon Pharmaceuticals Inc. announced it was seeking to open several outpatient clinics, offering PET imaging scans to help confirm the presence of amyloid plaques. Fast forward to today, and the company has now received accreditation and completed full enrollment in the U.S. Medicare and Medicaid programs.
Grey Matters Health—as the company is called—said it soon hopes to launch its first location in Davie, situated on the campus of the HCA Florida University Hospital.
“We have now reached the point in our commercialization pathway where we can begin introducing doctors and patients to the many features of our new clinic, including our brain-dedicated PET scan technology,” Christopher J. Moreau, CEO of Grey Matters Health, said in a statement Nov. 18. “Advanced image resolution and clarity for earlier diagnosis of neurodegenerative diseases … is the professional care and service message we will be delivering as we work to establish a chain of dedicated brain PET imaging clinics across the U.S.”
Moreau and colleagues believe the new “NovaScan Neuroimaging Clinic” is the “first of its kind in the U.S.” It will provide brain PET scans, aimed at aiding in the detection of Alzheimer’s disease and similar such clinical concerns. The company plans to utilize the FDA-cleared CareMiBrain system—a small scanner coupled with a comfortable chair, which does not require an integrated CT component to produce high-quality images. Grey Matters claims this results in 25% reduction in radiation exposure for patients.
Last year, the company also had touted plans to offer infusion services for Alzheimer’s drugs such as Kisunla and Leqembi. However, Wednesday’s announcement did not discuss plans for any other services, beyond PET imaging. Algernon Pharmaceuticals said in May 2025 that it hoped to eventually scale operations with 10 clinics in 2026 and 10 more franchised locations “in cities and states to be announced.”
Algernon has reportedly signed a five-year lease for the Florida space with an option to add five more years. The company also hopes to open additional outposts in its home country of Canada, subject to the CareMiBrain scanner earning regulatory approval there.
“Grey Matters will also be working with the manufacturer of the CareMiBrain PET scanner to secure Health Canada approval for this new technology,” according to the company’s website.
